Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchSipavibartSipavibart (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France

Loubet et al., Human Vaccines & Immunotherapeutics, doi:10.1080/21645515.2024.2387221
Aug 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies
Retrospective 47 immunocompromised patients in France showing no adverse events with sipavibart, an investigational long-acting monoclonal antibody, as COVID-19 pre-exposure prophylaxis. The patients had various immunosuppressive conditions, frequently with hypogammaglobulinemia and other comorbidities.
Loubet et al., 14 Aug 2024, retrospective, France, peer-reviewed, 6 authors. Contact: paul.loubet@chu-nimes.fr.
This PaperSipavibartAll
Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France
Paul Loubet, Benjamin Gaborit, Mathilde Salpin, Hèlene Gardeney, Ilies Benotmane, Thomas Systchenko
Human Vaccines & Immunotherapeutics, doi:10.1080/21645515.2024.2387221
France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.
Disclosure statement Paul Loubet has received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AstraZeneca, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Sanofi Pasteur. Contributors' statement PL : Conceptualization, methodology, analysis and original draft; PL, BG, MS, HG, IB, TS: writing -review and editing, All authors read, revised, and approved the final manuscript. He received his M.D., specializing in Infectious and Tropical Diseases, and his Ph.D. from the Université de Paris, with his research on diagnosing lower respiratory infections in adults. Corresponding author's bio His main areas of interest are respiratory infections in adults from prevention to diagnosis and treatment, respiratory viruses, epidemiology of vaccine-preventable diseases, vaccines, and HIV.
References
Evans, Dube, Lu, Yates, Arnetorp et al., Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study, Lancet Reg Health Eur, doi:10.1016/j.lanepe.2023.100747
Levin, Ustianowski, Wit, Launay, Avila et al., Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of covid-19, N Engl J Med, doi:10.1056/NEJMoa2116620
Suribhatla, Starkey, Ionescu, Pagliuca, Richter et al., Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients, Br J Haematol, doi:10.1111/bjh.18782
{ 'indexed': {'date-parts': [[2024, 8, 16]], 'date-time': '2024-08-16T00:09:20Z', 'timestamp': 1723766960531}, 'reference-count': 3, 'publisher': 'Informa UK Limited', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2024, 8, 14]], 'date-time': '2024-08-14T00:00:00Z', 'timestamp': 1723593600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'content-domain': {'domain': ['www.tandfonline.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2024, 12, 31]]}, 'DOI': '10.1080/21645515.2024.2387221', 'type': 'journal-article', 'created': {'date-parts': [[2024, 8, 15]], 'date-time': '2024-08-15T06:26:00Z', 'timestamp': 1723703160000}, 'update-policy': 'http://dx.doi.org/10.1080/tandf_crossmark_01', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Characteristics of the first immunocompromised patients to receive sipavibart as an early access ' 'treatment for COVID-19 pre-exposure prophylaxis in France', 'prefix': '10.1080', 'volume': '20', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-1218-9432', 'authenticated-orcid': False, 'given': 'Paul', 'family': 'Loubet', 'sequence': 'first', 'affiliation': [ { 'name': 'Virulence Bactérienne et Infections Chroniques, University ' 'Montpellier, Nîmes, France'}]}, { 'given': 'Benjamin', 'family': 'Gaborit', 'sequence': 'additional', 'affiliation': [ { 'name': 'Service des Maladies Infectieuses et Tropicales, CHU Nantes, ' 'Nantes, France'}]}, { 'given': 'Mathilde', 'family': 'Salpin', 'sequence': 'additional', 'affiliation': [{'name': 'Service de Pneumologie, AP-HP, Hôpital Bichat, Paris, France'}]}, { 'given': 'Hèlene', 'family': 'Gardeney', 'sequence': 'additional', 'affiliation': [{'name': 'Service d’Hématologie, CHU Poitiers, Poitiers, France'}]}, { 'given': 'Ilies', 'family': 'Benotmane', 'sequence': 'additional', 'affiliation': [ { 'name': 'Service de Néphrologie-Dialyse-Transplantation, CHU Strasbourg, ' 'Strasbourg, France'}]}, { 'given': 'Thomas', 'family': 'Systchenko', 'sequence': 'additional', 'affiliation': [{'name': 'Service d’Hématologie, CHU Poitiers, Poitiers, France'}]}], 'member': '301', 'published-online': {'date-parts': [[2024, 8, 14]]}, 'reference': [ { 'key': 'e_1_3_4_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.lanepe.2023.100747'}, {'key': 'e_1_3_4_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2116620'}, {'key': 'e_1_3_4_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/bjh.18782'}], 'container-title': 'Human Vaccines & Immunotherapeutics', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2387221', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 8, 15]], 'date-time': '2024-08-15T06:26:03Z', 'timestamp': 1723703163000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.tandfonline.com/doi/full/10.1080/21645515.2024.2387221'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 8, 14]]}, 'references-count': 3, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2024, 12, 31]]}}, 'alternative-id': ['10.1080/21645515.2024.2387221'], 'URL': 'http://dx.doi.org/10.1080/21645515.2024.2387221', 'relation': {}, 'ISSN': ['2164-5515', '2164-554X'], 'subject': [], 'container-title-short': 'Human Vaccines & Immunotherapeutics', 'published': {'date-parts': [[2024, 8, 14]]}, 'assertion': [ { 'value': 'The publishing and review policy for this title is described in its Aims & ' 'Scope.', 'order': 1, 'name': 'peerreview_statement', 'label': 'Peer Review Statement'}, { 'value': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=khvi20', 'URL': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=khvi20', 'order': 2, 'name': 'aims_and_scope_url', 'label': 'Aim & Scope'}, { 'value': '2024-07-04', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2024-07-28', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2024-08-14', 'order': 3, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit